The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1083 Ozempic articles
A groundbreaking case study involving deep brain activity recordings has shed light on how tirzepatide, known as Mounjaro and Zepbound, impacts the brain's reward center and its connection to food cravings and loss of control eating.
New research is shedding light on how GLP-1 medications, including popular drugs like Ozempic and Wegovy, influence brain pathways that control nausea, thirst, and reward-driven behaviors. This article delves into these findings and discusses potential strategies for managing common side effects.
A groundbreaking study published in The Lancet demonstrates that semaglutide, the active ingredient in Ozempic and Wegovy, provides substantial cardiovascular protection independent of the amount of weight lost. This finding reshapes our understanding of how these GLP-1 receptor agonists benefit heart health.
Discover how incretin-based therapies like Ozempic, Wegovy, and Mounjaro might be changing the way you experience food. This article delves into new research linking altered taste perception to reduced appetite and cravings, offering insights for patients and clinicians.
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
Beyond their well-known benefits for weight loss and diabetes management, popular GLP-1 medications such as Ozempic and Wegovy are now being studied for their potential impact on violent behavior. Emerging research from Rutgers University indicates a surprising link between these drugs and a reduction in actions associated with violence.
Discover how semaglutide, a popular GLP-1 medication, shows a surprising benefit in a recent study, potentially reducing bone fracture risk even as it aids in substantial weight loss for individuals with type 2 diabetes.
